Erythropoietin therapy is indicated primarily to treat anemia associated with:

• A. Iron deficiency anemia
• B. Anemia due to chronic kidney disease and chemotherapy
• C. Sickle cell anemia
• D. Aplastic anemia

Answer: (B)

Erythropoietin therapy is used when anemia results from the bone marrow not making enough red blood cells, either because the kidneys aren’t producing erythropoietin or because chemotherapy suppresses the marrow. In chronic kidney disease the kidneys fail to secrete adequate erythropoietin, so giving an erythropoiesis-stimulating agent stimulates red cell production and can reduce transfusion needs. In chemotherapy-induced anemia, the marrow is suppressed by cytotoxic therapy, and erythropoietin helps maintain hemoglobin levels by promoting RBC production. This approach hinges on having adequate iron available, since new red cells need iron to form; iron deficiency would limit the benefit of therapy and must be corrected.

This mechanism isn’t used as the primary treatment for iron deficiency anemia, sickle cell disease, or aplastic anemia, where addressing iron stores, preventing crises and transfusions, or using immunosuppressive therapy or marrow transplant are more appropriate strategies.